quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 3, 2025

Earnings live: Salesforce stock rises on upbeat guidance, Snowflake tumbles, American Eagle surges

View original at finance.yahoo.com
Earnings live: Salesforce stock rises on upbeat guidance, Snowflake tumbles, American Eagle surges The third quarter earnings season is winding down, and only a handful of major companies have yet to report results…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If 13.4% earnings growth holds, it would mark fourth straight quarter of double-digit earnings growth and acceleration from 12% in Q2

    80% confidence
  • Celestial AI acquisition further strengthens Marvell's position at forefront of fastest-growing opportunities in AI datacenter infrastructure

    80% confidence
  • Q3 sales were strongest in 13 quarters, reflecting acceleration of Bold New Chapter strategy and demonstrating enterprise-wide changes are resonating with customers

    80% confidence
  • Achieved three years of consecutive quarterly sales growth with record Q3 net sales up 7%. Hollister grew 16% on strong back-to-school and fall transition. Abercrombie made sequential progress, aiming for Q4 brand sales approximately flat to last year's record.

    80% confidence
  • Street is underestimating growth potential for CrowdStrike as second/third derivative beneficiary of AI Revolution. CrowdStrike is AI-powered cybersecurity businesses increasingly can't live without.

    80% confidence
  • Enterprises want AI that can work within secure, trusted data environments without compromise. Partnership brings Claude directly into Snowflake where data already lives.

    80% confidence
  • Analysts expected 7.9% jump in earnings per share in Q3 as of Sept. 30

    80% confidence
  • 95% of S&P 500 companies have reported Q3 earnings as of Nov. 21, and analysts expect 13.4% jump in earnings per share during third quarter

    80% confidence
  • S&P 500 companies with earnings beats saw stock price increase average 0.4% in four-day period around earnings release, less than five-year average of 0.9%

    80% confidence
  • 83% of S&P 500 earnings surprises were to the upside in Q3 2025

    80% confidence
  • 3 million more households are now part of Dollar Tree customer base compared to last year, with high-income consumers (>$100k/year) making up majority of new customers

    80% confidence
  • Q2 results are strongest in Credo's history, reflecting continued build-out of world's largest AI training and inference clusters. AI clusters now measured in hundreds of thousands of GPUs, soon millions.

    80% confidence
  • Strong momentum driven by all-around competitiveness of NIO, ONVO, and FIREFLY brand offerings. Expect Q4 deliveries of 120,000-125,000 units, up 65.1%-72.0% YoY, setting new quarterly record.

    80% confidence
  • Q3 was exceptional quarter. Existing customers expanding and net-new customer additions continue showing strength. Companies choosing MongoDB for unified data platform powering mission-critical workloads and AI platform shift.

    80% confidence
  • Companies reporting earnings below expectations saw stock decrease 5% on average, well below five-year average decrease of 2.6%

    80% confidence
  • All consumers are seeking value, marrying value-seeking behavior with convenience and discovery is where Dollar Tree thrives

    80% confidence
  • Strong momentum continued into Q4 with record-breaking Thanksgiving weekend led by acceleration in demand across brands and channels

    80% confidence

Data points we hold from this source

Salesforce · revenue10.27 billion_USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com